XTL Biopharmaceuticals Ltd. XTLB · Stock Open XTL Biopharmaceuticals Ltd. in new tab
XTL Biopharmaceuticals Ltd. Analysis (XTLB)
Is XTL Biopharmaceuticals Ltd. a good investment? XTL Biopharmaceuticals Ltd. (XTLB) is currently trading at 1.97 USD.
Investor FAQ
Does XTL Biopharmaceuticals Ltd. pay a dividend?
No, it does not currently pay a dividend.
What asset class is XTL Biopharmaceuticals Ltd.?
XTL Biopharmaceuticals Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 4, 2012 | 1:10 |
| Feb. 10, 2017 | 1:5 |
| Dec. 24, 2025 | 1:4 |
| March 25, 2026 | 1:4 |
Community Discussion